SCHEMBL4485722

SCHEMBL4485722

CCc1c(C#Cc2ccccc2Br)[nH]c(C=O)c1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
RAB9A P51151 2/20 0.40
IGF1R P08069 1/20 0.35
NR4A2 P43354 2/20 0.34
GAA P10253 3/20 0.33
TSHR P16473 3/20 0.33
LMNA P02545 2/20 0.33
FFAR1 O14842 1/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 3/20 0.33
NPSR1 Q6W5P4 3/20 0.33
HPGD P15428 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NFKB1 P19838 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489148 0.84 ALDH1A1 (0.46) ALDH1A1RAB9AIGF1RNR4A2GAA
SCHEMBL4490782 0.80 GRM5 (0.40) ALDH1A1RAB9AIGF1RNR4A2FFAR1
SCHEMBL13933342 0.77 RAB9A (0.43) ALDH1A1RAB9AIGF1RNR4A2GAA
SCHEMBL4481374 0.77 ALDH1A1 (0.41) ALDH1A1RAB9AIGF1RNR4A2GAA
SCHEMBL4482893 0.76 IGF1R (0.40) ALDH1A1RAB9AIGF1RLMNAMAPT
SCHEMBL4491721 0.76 IGF1R (0.45) ALDH1A1RAB9AIGF1RGAALMNA
SCHEMBL4490389 0.75 IGF1R (0.44) ALDH1A1RAB9AIGF1RLMNAMAPT
SCHEMBL4487447 0.74 ALDH1A1 (0.39) ALDH1A1RAB9ATSHRLMNAHTT
SCHEMBL4490766 0.74 IGF1R (0.39) ALDH1A1RAB9AIGF1RLMNAPOLB
SCHEMBL4493072 0.74 IGF1R (0.39) ALDH1A1RAB9AIGF1RLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504429-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-03-17 US claimed
EP-1651599-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2008-09-24 EP claimed
US-20060189577-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2006-08-24 US claimed
EP-1651599-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2006-05-03 EP claimed
WO-2005009957-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2005-02-03 WO claimed
US-7504429-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-03-17 US disclosed
US-7504429-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2009-03-17 US disclosed
EP-1651599-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2008-09-24 EP disclosed
US-20060189577-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2006-08-24 US disclosed
EP-1651599-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2006-05-03 EP disclosed
WO-2005009957-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189577-A1 Tyrosine kinase inhibitors ABL1, RET, ERBB2 ALDH1A1 2755/4885RAB9A 2642/4885IGF1R 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.